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Abstract
Introduction:  Inflammatory  conditions  of  the  nose  and  paranasal  sinuses  are  very  prevalent
in the  general  population,  resulting  in  marked  loss  of  quality  of  life  in  affected  patients,  as
well as  significant  work,  leisure,  and  social  activity  losses.  These  patients  require  specific  and
specialized  treatment.  A  wide  range  of  oral  medications  are  available.
Objective:  The  present  document  is  aimed  to  clarify,  for  professionals  treating  patients  with
inflammatory  sinonasal  diseases,  both  specialists  and  general  practitioners,  specific  oral  ther-
apies in  noninfectious  nasal  inflammatory  conditions.
Methods:  The  methodology  used  to  create  this  article  included  the  search  for  the  key  words:
oral corticosteroids,  antihistamines,  antileukotrienes,  rhinitis,  rhinosinusitis  in  the  MEDLINE  and
EMBASE databases  in  the  last  5  years.  Since  no  relevant  article  was  found  for  the  text  on  the
subject of  interest  in  the  last  5  years,  the  search  was  extended  for  another  5  years,  and  so  on,
according to  the  authors’  needs.
Results:  Relevant  literature  was  found  regarding  the  use  of  antihistamines,  antileukotrienes
and oral  corticosteroids  in  these  conditions.  The  Brazilian  Academy  of  Rhinology  emphasizes,
after extensive  discussion  by  the  collegiate,  key  points  in  the  treatment  with  these  drugs.
Conclusion:  There  is  support  in  the  literature  for  the  use  of  these  drugs;  however,  final  consid-
erations  about  the  role  of  each  of  them  have  been  made.
© 2017  Published  by  Elsevier  Editora  Ltda.  on  behalf  of  Associac¸a˜o  Brasileira  de  Otorrino-
laringologia  e  Cirurgia  Ce´rvico-Facial.  This  is  an  open  access  article  under  the  CC  BY  license
(http://creativecommons.org/licenses/by/4.0/).
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Posicionamento  da  Academia  Brasileira  de  Rinologia  sobre  o  uso  de  anti-histamínicos,
antileucotrienos  e  corticosteroides  orais  no  tratamento  de  doenc¸as inflamatórias
nasossinusais
Resumo
Introduc¸ão:  As  afecc¸ões  inflamatórias  do  nariz  e  seios  paranasais  são  muito  prevalentes  na
populac¸ão geral,  causam  acentuada  perda  de  qualidade  de  vida  dos  pacientes  afetados,  gerando
perdas significativas  das  atividades  de  trabalho,  lazer  e  sociais.  Estes  pacientes  necessitam  de
tratamento  específico  e  especializado  e  uma  ampla  gama  de  medicac¸ões  orais  estão  disponíveis.
Objetivo:  O  presente  documento  tem  por  objetivo  esclarecer  àqueles  que  tratam  das  doenc¸as
nasossinusais  inflamatórias,  tanto  especialistas  quanto  generalistas,  sobre  as  terapêuticas  orais
nas afecc¸ões  inflamatórias  nasais  não  infecciosas.
Método:  A  metodologia  utilizada  para  elaborac¸ão  deste  artigo  incluiu  a  busca  das  palavras
chave: corticosteroides  orais,  anti-histamínicos,  antileucotrienos,  rinite,  rinossinusite  nos  ban-
cos de  dados  MEDLINE  e  EMBASE  nos  últimos  5  anos.  Não  sendo  encontrado  artigo  relevante
para o  texto  sobre  o  assunto  de  interesse  nos  últimos  5  anos,  a  busca  poi  extendida  por  mais  5
anos, e  assim  por  diante,  de  acordo  com  a  necessidade  dos  autores.
Resultados:  Literatura  relevante  foi  encontrada  com  relac¸ão  ao  uso  dos  anti-histamínicos,
antileucotrienos  e  corticosteroides  orais  nestas  afecc¸ões.  A  Academia  Brasileira  de  Rinologia
resalta, após  amplo  debate  do  colegiado,  pontos-chave  no  tratamento  com  estes  medicamentos.
Conclusão:  Há  respaldo  na  literatura  para  o  uso  destes  medicamentos,  entretanto
considerac¸ões finais  acerca  do  papel  de  cada  deles  foram  feitas.
© 2017  Publicado  por  Elsevier  Editora  Ltda.  em  nome  de  Associac¸a˜o  Brasileira  de  Otorrino-
laringologia  e  Cirurgia  Ce´rvico-Facial.  Este e´  um  artigo  Open  Access  sob  uma  licenc¸a  CC  BY
(http://creativecommons.org/licenses/by/4.0/).
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Introduction
Inflammatory  conditions  of  the  nose  and  paranasal  sinuses
are  the  most  prevalent  group  of  diseases  in  the  general  pop-
ulation.  These  diseases,  such  as  allergic  and  non-allergic
rhinitis,  acute  and  chronic  rhinosinusitis,  with  and  without
nasal  polyposis,  result  in  a  marked  decrease  in  the  quality  of
life  of  affected  patients,  generally  causing  significant  work,
leisure,  and  social  activity  losses.  These  patients  require
specific  and  specialized  treatment.
Oral  medications  are  extremely  important  in  the  treat-
ment  of  inflammatory  diseases  of  the  nose  and  paranasal
sinuses,  as  well  as  in  the  treatment  of  infectious  diseases
of  the  upper  airways.  Although  some  classes  of  drugs  have
been  used  for  decades,  new  molecules  have  recently  been
made  available.
Due  to  the  prevalence  of  these  diseases,  there  are  very
high  direct  and  indirect  costs  associated  with  treatment,
especially  in  the  long  term.  The  cost  associated  with  treat-
ment  should  not  be  ignored,  and  the  correct  use  of  these
drugs  can  result  in  lower  costs  for  both  the  patients  and
their  families,  as  well  as  for  public  health  and  society.
The  aim  of  this  document  is  to  clarify  for  professionals
who  treat  inflammatory  sinonasal  diseases,  both  special-
ists  and  general  practitioners,  nasal  oral  therapies  for  these
noninfectious  diseases.  Through  a  review  of  the  scientific
evidence,  the  Brazilian  Academy  of  Rhinology  provides  a
practical  and  up-to-date  view  of  the  most  frequently  used
nasal  oral  medications,  except  for  medications  that  have
antimicrobial  agents  in  their  formulation.
The  methodology  used  to  create  this  article  included
the  search  for  the  key  words:  oral  corticosteroids,  antihis-
tamines,  antileukotrienes,  rhinitis,  and  rhinosinusitis  in  the
MEDLINE  and  EMBASE  databases  in  the  last  5  years.  No  article
was  found  relevant  to  the  text  on  the  subject  of  interest  in
the  last  5  years  and,  therefore,  the  search  was  extended  to
another  5  years,  and  so  on,  according  to  the  authors’  needs.
The role of histamine and leukotrienes in
nasal inflammatory diseases
HistamineHistamine  has  an  important  physiological  role  and  can
bind  to  4  different  receptors1 (Table  1).  Through  these
Table  1  Antihistamines  and  histamine  receptors.
Receptors  G  Protein  Main  activity
H1  Gq  Atopy  --  Gell
and  Coombs
Type  I  Reaction
H2 Gs  Digestive  tract
H3 Gi  Central  nervous
system
H4 Gi  Chemotaxis  of
eosinophils  and
mast  cells
Adapted from the III Consensus on rhinitis.1
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indings,  it  acts  on  immunoregulation  and  allergic  inflam-
ation.  In  allergic  rhinitis,  the  histamine  released  into  the
asal  mucosa  binds  to  H1  receptors  and  triggers  vasodila-
ion,  increased  vascular  permeability,  pruritus,  increased
landular  secretion,  and  nerve-ending  stimulation.
Histamine  receptors  are  classified  as  G-protein  receptors
n  active  or  inactive  form.  Histamine  stabilizes  its  active
tructuring,  while  antihistamines,  acting  as  inverse  agonists,
tabilize  the  inactive  conformation.2
eukotrienes
vidence  of  the  role  of  leukotrienes  in  disease  pathophysi-
logy  comes  from  studies  of  the  immediate  and  late  phases
n  allergen-triggering.  That  did  not  happen  after  contact
ith  methacholine.3,4 Analysis  of  the  secretion  of  patients
ith  persistent  rhinitis  showed  high  levels  of  C4  and  D4  cys-
eine  leukotrienes5 and  LTC4.6 Due  to  the  intense  capacity
f  leukotrienes  to  cause  inflammation,  which  is  thousands  of
imes  greater  than  that  of  histamine,  it  has  been  speculated
hat  nasal  obstruction  and  congestion  are  directly  associated
ith  this  class  of  mediators7 (Fig.  1).
Nasal  polyposis  is  a  chronic  inflammatory  disease  of  the
pper  respiratory  tract  that  affects  2--4%  of  the  popula-
ion  and  2/3  of  patients  with  acetylsalicylic  acid-sensitive
sthma.  The  histology  of  polyps  is  similar  to  that  of  asthma,
ith  abundant  eosinophils,  mast  cells,  and  high  levels  of
roinflammatory  cystenyl  leukotrienes.8
It  has  been  proposed  that  one  of  the  potential  causes
f  chronic  rhinosinusitis  with  nasal  polyps  is  the  presence
f  defects  in  the  eicosanoid  pathway,  more  strongly  associ-
ted  with  acetylsalicylic  acid  intolerance.9 Specifically,  the
ncreased  synthesis  of  pro-inflammatory  leukotrienes  and
he  decreased  synthesis  of  anti-inflammatory  prostaglandins
ave  been  the  accepted  mechanism,  not  only  for  chronic  rhi-
osinusitis  with  nasal  polyps  in  acetylsalicylic  acid-sensitive
atients  but  also  in  those  tolerant  to  this  drug.10
Regarding  leukotrienes  and  chronic  rhinosinusitis,  there
re  many  data  about  their  action  on  inflammation  reduction,
specially  concerning  eosinophils  and  eicosanoid  pathway.11
ontelukast  showed  a  reduction  in  eosinophilic  inflamma-
ion,  cytokine  viability  and  production  in  nasal  polyps.12 It
as  been  demonstrated  that  calcium  (Ca+)  influx  into  mast
ells  through  the  activation  of  Ca+ channels  release  stim-
lates  the  production  of  C4  leukotrienes,  which  in  turn
ctivates  a  higher  Ca+ influx.13
ntihistamines
ntihistamines  are  considered  the  gold  standard  medication
or  the  treatment  of  allergic  rhinitis.2
They  decrease  the  allergic  inflammatory  reaction  through
heir  action  on  H1  receptors,  by  interfering  with  the
ction  of  histamine  on  sensory  neurons  and  small  ves-
els.  The  kappa-beta  nuclear  transcription  factor  inhibition
lso  reduces  the  antigenic  presentation,  the  expression  of
ytokines  and  cell  adhesion  molecules.  They  also  reduce
ast  cell  activation  in  a  dose-dependent  manner.11
H1  antihistamines  are  classified  into  two  groups.  The
rst-generation  drugs  rapidly  cross  the  blood--brain  bar-
ier  and  occupy  H1  receptors  located  on  the  postsynaptic
218  Mion  OG  et  al.
Arachidonic
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FLAP
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Transmembrane
transporter
Nucleus Zileuton
5-lipoxigenase
Leukotriene A4 Leukotriene C4
Leukotriene C4
Leukotriene B4
Leukotriene D4
BLT Receptor
ChemotaxisExtracellular
space
Leukotriene E4
CysLT1
Receptor
Leukotriene C4
synthase
Montelukast
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Cell membranes Nuclear membrane
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 leading  to  leukotriene  formation.
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Table  2  Second-generation  antihistamines  and  effects  on
the central  nervous  system.
Drug  Doses  mg  Sedation  observed  in
studies  on  rhinitis  or
urticaria,  alone
Bilastine  20  1.8--5.8%
Cetirizine  10  6--8.5%
Desloratadine  5  1.1--3.7%
Ebastine  10  1.4--2.7%
20  <2--3%
Fexofenadine  120  <2--3%
180  1.7--4.5%
Levocetirizine  5  0.7--6.7%
Loratadine  10  2.2--6.6%
Rupatadine  10  2.7--10%Figure  1  Eicosanoid  pathway
embrane  of  histaminergic  neurons.  Most  of  these  anti-
istamines  were  marketed  before  pharmacological  studies
ere  required  by  regulatory  agencies  thus,  pharmacokinetic
nd  pharmacodynamic  data  are  not  available  for  most  of
hem.11
On  the  other  hand,  second-generation  drugs  create  a
ower  potential  for  sedation  (Table  2)  and  pharmacoki-
etic  and  pharmacodynamic  data  have  been  published  for
everal  groups,  such  as  healthy  adults,  the  elderly,  chil-
ren,  patients  with  renal  failure,  etc.  (Table  3).  Similarly,
heir  interaction  with  food  and  other  drugs  is  known.  It  is
mphasized  that  after  intake  discontinuation,  the  histamine
esponse  suppression  in  the  allergic  tests  lasts  from  1  to  5
ays.11
The  potential  adverse  effects  of  first-generation  antihis-
amines  can  be  divided  according  to  their  action  on  other
eceptors,  as  shown  in  Table  4.There  is  strong  scientific  evidence  for  their  action  in
mproving  allergic  rhinitis  and  allergic  rhinoconjunctivitis
ymptoms.2,11,14 Second-generation  antihistamines  prevent
Table  3  Pharmacokinetics  and  pharmacodynamics  of  some  antih
Generation  Tmax (h)  Half-li
Chlorpheniramine  1st  2.8  27.9  
Diphenhydramine  1st  1.7  9.2  
Hydroxyzine  1st  2.1  20.0  
Bilastine 2nd  1.2  14.5  
Cetirizine 2nd  1.0  6.5  
Desloratadine  2nd  1--3  27  
Fexofenadine  2nd  1--3  11  
Levocetirizine  2nd  0.8  7  
Loratadine  2nd  1.2  7.8  
Rupatadine  2nd  0.75  6  
Adapted from Simons and Simons.2Adapted from Simons and Simons.2
istamines  in  adults.11
fe  (h)  Start  of  action  (h)  Duration  of  effect  (h)
3  24
2  12
2  24
2  24
0.7  ≥24
2--2.6  ≥24
1--3  24
0.7  >24
2  24
2  24
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Table  4  Potential  adverse  effects  of  first-generation
antihistamines.2
Action  site  Effect
H1  receptor  in
central  nervous
system
Sedation  and  decreased
attention,  cognition,  learning,
memory  and  psychomotor
performance
Muscarinic
receptor
Dry  mouth  and  eyes,  urinary
retention,  sinus  tachycardia,
mydriasis,  and  constipation
Serotonin  receptor  Increased  appetite  and  weight
gain
Alpha-adrenergic
receptor
Dizziness  and  postural
hypotension
Cardiac  ion
channels
Increased  QT  interval  and
ventricular  arrhythmia
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in  a  single  tablet.
Some  studies,  mostly  directed  at  rhinitis,  have  shownAdapted from Simons and Simons.
and  improve  symptoms  such  as  sneezing,  nasal  pruritus,  and
rhinorrhea,  which  characterize  the  immediate  response  of
the  Gell  and  Coombs  Type  I  allergic  reaction  classification.
However,  they  show  a  diminished  effect  on  nasal  congestion
(late  phase)  (Table  5).  They  also  control  ocular  symptoms
such  as  erythema,  tearing,  pruritus  and  edema.2,11,14
According  to  the  American  Academy  of  Otorhinolaryngol-
ogy  and  Head  and  Neck  Surgery  and  the  Allergic  Rhinitis
and  Its  Impact  on  Asthma  consensus,  it  is  recommended
to  use  second-generation  oral  antihistamines  for  patients
with  allergic  rhinitis.  Although  they  are  not  as  effective
as  intranasal  corticosteroids,  antihistamines  possess  the
advantage  of  cost,  rapid  action  onset,  and  maintenance  of
efficiency  with  regular  use  in  mild  and  moderate  cases.  Their
greatest  benefit  comes  with  regular  use;  however,  their
administration  ‘‘when  necessary’’  is  of  great  usefulness  as
temporary  rescue  medication.2,14
The  first  and  second-generation  antihistamine  doses  for
adults  and  children  are  shown  in  Table  6.
Antihistamines  are  not  recommended  in  the  treatment
of  acute  bacterial  rhinosinusitis,16 but  they  can  be  used
for  relieving  sneezing  and  rhinorrhea  symptoms  in  viral
cases.8 In  patients  with  chronic  rhinosinusitis,  with  or  with-
out  polyposis,  there  is  no  recommendation  for  the  use  of
oral  antihistamines,  except  in  allergic  patients.  According
to  evidence-based  medical  studies,  there  is  improvement  in
clinical  and  endoscopic  scores  in  these  patients.8
The  intake  of  first-generation  antihistamines  may  occa-
sionally  cause  intense  dizziness,  confusion,  delirium,  coma,
and  respiratory  depression.  In  children,  on  the  other  hand,
t
s
Table  5  Effect  of  medications  on  allergic  rhinitis  symptoms.
Sneezing  Rhinorrhe
Oral  antihistamines  ++  ++  
Oral decongestants  
Antileukotrienes  +  +  
Modified from the III Consensus on Rhinitis and American Academy of O219
here  may  be  paradoxical  effects,  such  as  excitement,  irri-
ability,  hyperactivity,  insomnia,  and  hallucination.2
In  contrast,  the  second-generation  drugs,  at  the  usual
oses,  are  practically  free  of  adverse  effects  on  the  central
ervous  system  and  action  on  the  muscarinic,  serotonin  and
lpha-adrenergic  receptors.11 Their  safety  in  special  popu-
ations  is  described  in  Table  7.
econgestants  associated  with  antihistamines
asal  decongestants  are  subdivided  into  oral  and  topical
ormulations.  As  they  are  alpha-adrenergic  agonists,  their
ain  effect  is  vasoconstriction.1 Pseudoephedrine  is  the
ost  commonly  used  decongestant,  in  combination  with
ntihistamines  (Tables  8  and  9).  This  combination  has  a
etter  effect  than  each  drug  alone  in  controlling  nasal  symp-
oms,  but  the  chance  of  adverse  effects  such  as  insomnia,
eadache,  dry  mouth,  and  irritability  increases.17,18 Their
se  reduces  hyperemia,  edema  and  nasal  congestion18 and
heir  safety  is  known  in  single  daily  doses  of  up  to  240  mg  for
he  control  of  nasal  obstruction  in  seasonal  allergic  rhinitis,
ther  respiratory  allergies  and  rhinosinusitis.18
A  recent  study  carried  out  by  the  Food  and  Drug  Admin-
stration  (FDA)  to  evaluate  the  efficacy  of  phenylephrine  in
ontrolling  nasal  obstruction  has  shown  that  it  has  a  similar
ffect  to  placebo  when  given  at  a  dose  of  up  to  40  mg  every
 h.19
There  is  no  evidence  for  the  efficacy  of  decongestants  in
ases  of  acute  bacterial  rhinosinusitis  in  children  or  adults,
s  well  as  in  patients  with  chronic  rhinosinusitis  (with  or
ithout  polyposis).20,21
Pseudoephedrine  has  minimal  hepatic  metabolism  and
s  eliminated,  unaltered,  in  the  urine.  Its  half-life  is
--8  h.21,22 Oral  decongestants  should  be  prescribed  with
aution  to  the  elderly,  children,  patients  with  a history  of
ardiac  arrhythmia,  angina  pectoris,  cerebrovascular  dis-
ase,  hypertension,  urinary  retention,  hyperthyroidism  and
hould  be  avoided  in  patients  with  prostatic  hypertrophy  and
thletes,  since  it  is  considered  doping.23,24
ntihistamines  associated  with  antileukotrienes
n  antihistamine--antileukotriene  association  has  been
ecently  launched  in  the  market.  Its  objective  is  to  improve
he  clinical  effect  of  the  drugs,  either  by  association  or
otentiation  of  effect.  Additionally,  it  can  improve  adher-
nce  to  treatment  by  offering  two  different  classes  of  drugshat  montelukast  has  been  associated  with  a  variety  of
econd-generation  antihistamines,  such  as  loratadine,25,26
a  Nasal  obstruction  Nasal  pruritus
+  +++
+++
+  +
torhinolaryngology and Head and Neck Surgery.1
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Table  6  Antihistamine  presentation  and  doses.
Anti  H1  Presentation  Doses
Children  2--12  years  12  years
Classic  (first  generation)
Clemastine  Syrup:  5  mg/mL
Tablet:  1  mg
<1  year:  2.5  mL  12/12  h
1--3 years:  2.5--5  mL  12/12  h
3--6  years:  5  mL  12/12  h
6--12  years:  7.5  mL  12/12  h
20  mL  12/12  h
1  tablet  12/12  h
Dexchlorpheniramine  Syrup:  25  mg/mL
Tablet:  2  mg
Pill:  6  mg
6  years:  1.2  mL  8/8  h
6--12  years:  2.5  mL  8/8  h
5  mL  or  1  tablet  8/8  h
Maximum  of  12  mg/day
Hydroxyzine Syrup  or  tablet  Up  to  6  years:  50  mg/day
>6  years:  up  to  100  mg/day
Up  to  150  mg/day
Promethazine  Syrup:  5  mg/5  mL
Tablet:  25  mg
1  mg/kg/day  2--3  times/day  20--60  mg/day
Cyproheptadine  Elixir:  2  mg/5  mL
Tablet:  4  mg
2--6  years:  2  mg  8/8  h
Maximum  8  mg/day
6--12  years:  4  mg  8/8  h
Maximum  16  mg/day
4  mg  8/8  h
Maximum  16  mg/day
Non-classic  (second  generation)
Loratadine  Oral  solution:  5  mg/5  mL
Tablet:  10  mg
>2  years:  <30  kg:  5  mg/day
>30  kg:  10  mg/day
10  mg/day
Cetirizine Drops:  10  mg/mL
Tablet:  10  mg
2--6  years:  2.5  mg/dose
12/12  h
6--12  years:  5  mg/dose
12/12  h
10  mg/day
Rupatadine  Tablet:  10  mg  --  10  mg/day
Epinastine Syrup:  10  mg/5  mL
Tablet:  10  mg
Tablet:  20  mg
6--12  years:  5--10  mg/day  20  mg/day
Levocetirizine  Drops:  5  mg/mL
Tablet:  5  mg
6  years:  1.25  mg/dose
12/12  h
6--12  years:  5  mg/day
5  mg/day
Desloratadine  Oral  solution:  2.5  mg/5  mL
Tablet:  5  mg
2--5  years:  1.25  mg/d
6--11  years:  2.5  mg/day
5  mg/day
Ebastine Syrup:  1  mg/mL
Tablet:  10  mg
2--6  years:  2.5  mg/day
6--12  years:  5  mg/day
10  mg/day
Fexofenadine  Oral  solution:  6  mg/mL
Capsules:  60  mg
Tablet:  120  mg
6  months--2  years:
15  mg/dose  12/12  h
2--11  years:  30  mg/dose
12/12  h
60  mg  12/12  h
120  mg/d
Bilastine Tablet:  20  mg  --  20  mg/day
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exofenadine,27 desloratadine28 and  cetirizine.29 A  meta-
nalysis  has  shown  that  their  clinical  effect  is  superior
o  that  of  placebo.30 Other  studies  have  shown  that
he  combination  is  superior  to  that  of  antihistamines
r  antileukotrienes  alone  in  controlling  allergic  rhinitis
ymptoms.29,31
Few  studies  have  evaluated  the  combination  of  lev-
cetirizine  and  montelukast,  but  the  results  have  been
romising,  superior  to  the  associations  with  other  antihis-
amines.  The  combination  of  levocetirizine  and  montelukast
howed  superior  results,  with  a  beneficial  additive  effect
n  the  treatment  of  persistent  allergic  rhinitis.32,33 There
re  studies  showing  that  such  a  combination  brings  benefits
r
a
i
in  preventing  symptoms  in  patients  with  poor  response  to
onotherapy  and  in  controlling  symptoms,  especially  noc-
urnal  ones.34,35
eukotriene antagonists
he  leukotriene  receptor  antagonist,  montelukast,  is  used
n  the  control  of  allergic  diseases,  such  as  asthma  and
hinitis,  as  it  is  a  receptor  blocker  that  binds  with  high
ffinity  and  selectivity  to  the  cysteine  receptors  found
n  the  airways.36,37 It  has  no  bronchodilator  effect,  but
t  improves  lung  function  of  patients  with  moderate  and
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Table  7  Adverse  effects  in  special  populations.11
1st  generation  2nd  generation
Renal/liver  failure  Few  studies.  It  may  be  potentially
associated  with  adverse  effects.
Data  evaluated  for  each  drug.  The  drug
package  leaflet  should  be  consulted  for
possible  dose  changes.
Elderly Impairs  cognition,  memory  and  attention.  It
can  lead  to  falls,  delirium,  and
incontinence.
Data  evaluated  for  each  drug.  The  drug
package  leaflet  should  be  consulted  for
more  information.
Pregnant  women  Diphenhydramine  and  chlorpheniramine  are
classified  as  Class  Ba drugs  (FDA).  Irritability
and drowsiness  have  been  reported  in
infants.
Cetirizine  and  loratadine  are  classified  as
Class Ba drugs  (FDA).  Desloratadine,
fexofenadine  and  levocetirizine  are  Class  Ca
drugs  (FDA).  No  adverse  effects  have  been
reported  in  infants.
Neonates  May  cause  irritability,  drowsiness  and
respiratory  depression.
No  effect  on  central  nervous  system.
Children Potential  risk  of  adverse  effects.  Long-term  safety  for  cetirizine,
desloratadine,  fexofenadine,  levocetirizine
and  loratadine  has  been  demonstrated.
Adapted from Simons and Simons.2
a Risk classification of drug use in pregnancy, according to the Food and Drug Administration (FDA). Category A -- adequate and well-
controlled studies have not shown any risk to the fetus in the first trimester of pregnancy (there is no evidence of risk in other trimesters);
B -- studies on animal reproduction have not shown a risk to the fetus and there are no adequate and well-controlled studies in pregnant
women; C -- animal reproduction studies have demonstrated adverse effects on the fetus and there are no adequate and well-controlled
studies in humans; however, the potential benefits may justify the drug use in pregnant women despite the potential risks; D -- there is
evidence of risk to the fetus based on adverse reactions from investigational studies or post-marketing studies; however, the potential
benefits may justify the drug use in pregnant women despite the potential risks; X -- animal or human studies have demonstrated
fetal alterations or evidence of risk to the human fetus based on adverse reactions from investigational or post-marketing studies and
stify 
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http://www.drugs.com/pregnancy-categories.html [accessed 02.
severe  asthma,38 In  addition  to  improving  the  symptoms
of  rhinitis,39 sleep  apnea,40 and  conjunctivitis,41 and  may
be  used  as  adjunctive  therapy  in  chronic  urticaria.42 The
GINA  (Global  Initiative  for  Asthma),43 PRACTALL  (Practicing
Allergology)44 and  ARIA  (Allergic  rhinitis  and  its  impact  on
asthma)11 guidelines  recommend  the  use  of  montelukast  as
a  therapeutic  agent  for  the  control  of  asthma  and  rhinitis.
Affinity  and  selectivity  for  the  cysteine  receptor
When  montelukast  binds  with  high  affinity  and  selectivity
to  cysteine  receptors  (CysLT),  it  promotes  the  physiolog-
ical  blocking  of  leukotrienes  C1  to  C4,  D  and  E.  This
binding  does  not  occur  with  other  respiratory  receptors
(cholinergic,  prostanoid,  beta-adrenergic).  Montelukast,  as
well  as  another  leukotriene  antagonist,  zafirlukast,  are  also
potent  ligands  of  the  CysLT  receptor,  more  strongly  than
pranlukaste  and  other  equivalent  compounds  (LM-1507  and
LM-1484).45
Safety  and  side  effects
Montelukast  has  shown  to  be  a  drug  with  a  high  safety  pro-
file  and  is  recommended  for  the  treatment  of  asthma  and
rhinitis  by  consensus  and  global  guidelines.11,44,45 The  over-
all  incidence  of  adverse  events  is  considered  low  (Table  10).
The  Cochrane  Foundation  rated  the  drug  as  being  safer  than
long-acting  beta-2  agonists.46
a
N
uthe potential benefits. FDA Pregnancy Categories. Available at:
].
fficacy  of  montelukast  in  allergic  rhinitis
everal  studies  since  the  1990s  have  investigated  the  possi-
le  efficacy  of  leukotriene  antagonists  in  the  treatment  of
llergic  rhinitis.58,59
The  antagonist  zafirlukast  was  evaluated  in  allergic
hinitis,  which  showed  some  protection,59 as  well  as
ranlukaste.60 The  use  of  montelukast  resulted  in  greater
fficacy,  including  good  cost--benefit,61 although  it  is  less
ffective  than  nasal  corticosteroids.35
Several  authors  have  evaluated  the  action  of  montelukast
n  studies  with  more  than  1000  patients  with  seasonal62,63
nd  persistent  rhinitis,64 confirming  the  improvement  of  all
ardinal  symptoms  of  allergic  rhinitis,  with  effect  on  sleep
nd  quality  of  sleep,  ocular  symptoms,  allergic  rhinocon-
unctivitis  and  quality  of  life  in  general.60,62--64
The  efficacy  of  antileukotrienes  in  allergic  rhinitis  and
sthma,  after  more  than  15  years  of  use,  has  been  widely
emonstrated.  Montelukast  has  been  very  well  evaluated
or  the  treatment  of  seasonal  and  perennial  allergic  rhini-
is.  It  results  in  significant  improvements  in  nasal  and  ocular
ymptoms  between  1  and  3  days,  as  well  as  in  nocturnal
ymptoms,  sleep  quality  and  quality  of  life.60
ntileukotrienes  and  chronic  rhinosinusitis  with
nd without  nasal  polyps
asal  polyposis  is  a  chronic  inflammatory  disease  of  the
pper  respiratory  tract  affecting  2--4%  of  the  population
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Table  8  Association  of  first-generation  antihistamines  with  decongestants.1
Association  Presentation  Doses  for  children  Doses  for  adults  and
children  older  than
12  years
Azatadine  +  pseudoephedrine  Pill  1  mg  azatadine  +  120  mg
pseudoephedrine
Syrup  0.5  mg  azatadine  +  30  mg
pseudoephedrine/mL
>6  years:  5  mL  every
12 h
1--6  years:  2.5  mL
every  12  h
1  tablet  every  12  h
10--20  mL  every  12  h
Brompheniramine  +  phenylephrinea Syrup  5  mL  with  2  mg
brompheniramine  +  5  mg
phenylephrine
Drops  1  mL  with  2  mg
brompheniramine  +  2.5  mg
phenylephrine
Tablet:  12  mg
brompheniramine  +  15  mg
phenylephrine
>2  years:  2.5--5  mL
every  6  h
>2  years:  2  drops  per
kg  divided  every  8  h
15  --30  mL  every  6  h
1 tablet  every  12  h
Brompheniramine  +  pseudoephedrine  Syrup  1  mL  with  0.2  mg
brompheniramine  +  3  mg
pseudoephedrine
Capsules  with  4  mg
brompheniramine  +  60  mg
pseudoephedrine
>6  months:
0.25--0.30  mL/kg/dose
every  6  h
20  mL  every  6  h
1  capsule  every  6  h
Triprolidine +  pseudoephedrine Syrup:  every  5  mL
1.25  triprolidine  +  30  mg
pseudoephedrine
Tablet:  2.5  mg  triprolidine  +  60  mg
pseudoephedrine
2--5  years:  2.5  mL
every  6  h
6--12  years:  5  mL
every  6  h
10  mL  every  6  h
1  tablet  every  6  h
Adapted from III Consensus on rhinitis.1
a No evidence of clinical effect on nasal obstruction.
Table  9  Association  of  second-generation  antihistamines  with  oral  decongestants.1
Association  Presentation  Doses  for  children  Doses  for  adults  and
children  older  than
12  years
Fexofenadine  +  pseudoephedrine  Tablet  60  mg  +  120  mg
pseudoephedrine
1  tablet  every  12  h
Loratadine +  pseudoephedrine Tablet  5  mg
loratadine  +  120  mg
pseudoephedrine
Weight  >  30  kg:
5 mL  every  12  h
Weight  <  30  kg:
2.5  mL  every  12  h
1  tablet  every  12  h
Tablet 24  h  10  mg
loratadine  +  240  mg
pseudoephedrine
Syrup  1  mg
loratadine  +  12  mg
pseudoephedrine/mL
1  tablet/day
Ebastine +  pseudoephedrine  Capsules  10  mg
ebastine  +  120  mg
pseudoephedrine
1  tablet  every  12  h
Desloratadine  +  pseudoephedrine  Capsules
2.5  mg  +  pseudoephedrine
1  tablet  every12  h
Cetirizine +  pseudoephedrine  Capsules  5  mg  +  120  mg
pseudoephedrine
1  tablet  every  12  h
Treatment  of  inflammatory  sinonasal  diseases  
Table  10  Side  effects  of  antileukotrienes.48--59
Adverse  effects  of  montelukast
Overall  effects  Pharyngitis,  fever,
infection
Comparable  to
placebo47
Effects  on  lower
airways
Worsening  of
asthma
Comparable  to
placebo47
Effects  on  central
nervous  system
Irritability,
aggressiveness,
hallucinations
Suicide?
Related  to
other  drugs
used  together?
Symptom
improvement
after  treatment
discontinuation48--52
Vascular  system  Churg-Strauss
Syndrome?
(Vasculitis)
Angioedema
Not  fully
clarified53,54
Skin  Urticaria 53
Hepatic  Hepatitis 53,55
High  doses  of  up
to 1000  g
Malaise,  vomiting,
abdominal  pain
and  hyperactivity
No  serious
accounts  in
relation  to
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82,83overdose56,57
and  2/3  of  asthmatic  patients  with  acetylsalicylic  acid
sensitivity.8
Although  the  pathophysiology  of  chronic  rhinosinusitis
suggests  the  use  of  antileukotrienes,  double-blind  ran-
domized  clinical  trials  do  not  support  theoretical  studies
regarding  the  efficacy  of  leukotriene  inhibitors  so  clearly.65
Leukotriene  antagonists,  such  as  montelukast,  zafirlukast
and  zileuton  were  evaluated  in  studies  involving  patients
with  chronic  rhinosinusitis  with  nasal  polyposis  and  Aspirin-
Exacerbated  Respiratory  Disease  (AERD).66,67 The  results
were  not  clear.  Many  uncontrolled  open  studies  have  sug-
gested  the  benefits  of  antileukotrienes  in  symptomatology,
nasal  polyp  size  and  tomographic  scores.68 Other  results
include  significant  improvement  in  headache,  pain  and  facial
pressure,  auditory  discomfort,  dental  pain,  purulent  nasal
discharge,  post-nasal  drip,  nasal  congestion  and  obstruction,
as  well  as  olfactory  symptoms.69 These  studies  conclude
that  leukotriene-modifying  drugs,  if  added  to  standard  med-
ications,  including  corticosteroids,  result  in  improved  nasal
symptoms  in  patients  with  chronic  rhinosinusitis  with  and
without  polyposis.70--72
However,  data  from  double-blind,  randomized  con-
trolled  studies  do  not  consistently  support  the  benefit
of  antileukotriene  therapy  in  patients  with  chronic
rhinosinusitis.66,73 Although  antileukotrienes  are  effective
in  patients  with  AERD,  they  are  no  more  effective  than  in
acetylsalicylic  acid-tolerant  patients.74,75
Regarding  the  association  of  montelukast  with  intranasal
corticosteroids,  there  are  studies  that  demonstrate  the
efficacy  of  their  combined  use  in  chronic  rhinosinusitis.
Montelukast  added  to  intranasal  corticosteroids  improves
symptoms  in  patients  with  chronic  rhinosinusitis,  with  an
excellent  safety  profile.76
For  these  reasons,  the  action  of  antileukotrienes,  when
analyzed  from  the  point  of  view  of  evidence-based  Medicine,
a
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iscloses  a  limited  level  of  efficacy  and  has  a  low  degree  of
ecommendation  in  patients  with  chronic  rhinosinusitis  with
asal  polyposis.77
Montelukast  was,  to  date,  the  most  commonly  used
ntileukotriene.  Its  anti-inflammatory  action,  especially
hose  related  to  the  eosinophil  and  its  cytokines  has  been
emonstrated  by  several  studies.  Another  important  factor
hen  considering  montelukast  is  its  high  safety  and  toler-
bility,  even  in  children.11 What  is  clearly  understood  is  its
sefulness  in  allergic  patients  with  asthma  and  patients  with
cetylsalicylic  acid  intolerance.  These  are  the  patients  with
hronic  rhinosinusitis  who  should  receive  antileukotrienes
herapy,  either  as  an  adjunctive  therapy  or  not,  in  the  post-
perative  and  maintenance  periods.
ral corticosteroids
lucocorticosteroids  (GCs)  are  a  class  of  drugs  with  effects
n  several  cell  functions,  and  their  important  effect  on  the
echanisms  involved  in  inflammation  make  them  one  of  the
ain  modalities  of  treatment  in  autoimmune  and  inflamma-
ory  diseases,  such  as  asthma,  allergy,  rheumatoid  arthritis,
ultiple  sclerosis,  and  inflammatory  bowel  diseases.78 This
haracteristic  also  provides  a relevant  role  in  nasal  inflam-
atory  diseases.  However,  their  therapeutic  benefits  are
imited  by  the  side  effects  associated  with  their  prolonged
se  and  high  doses.
These  effects  include  osteoporosis,  skin  atrophy,  dia-
etes,  glaucoma,  cataracts,  hypertension,  avascular  necro-
is,  infection  and  increased  abdominal  fat.79 Table  11  shows
he  main  systemic  GCs  used  in  clinical  practice  with  their
quivalence  table  and  anti-inflammatory  potency.80 We  use
he  terminology  ‘‘corticosteroid’’  (CS)  as  synonymous  with
C.
Corticosteroids  act  on  protein  synthesis.  When  they
enetrate  the  cells,  they  bind  to  receptors  called  glucocor-
icosteroid  receptors  and  go  into  the  cell  nucleus,  where
hey  trigger  genomic  effects.  They  have  two  action  mecha-
isms:  the  first  is  called  transactivation,  when  it  induces  the
ynthesis  of  proteins  such  as  lipocortin-1,  beta-adrenergic
eceptors,  secretory  leukoprotease  inhibitor.  They  also  have
 transrepression  action,  where  there  is  inhibition  of  syn-
hesis  of  inflammatory  cytokines  and  adhesion  molecules,
mong  others.  Such  mechanism  seems  to  be  the  most  rele-
ant  in  inflammatory  diseases,  and  also  the  least  related  to
he  adverse  effects  of  this  class  of  drugs.1,81
cute  bacterial  rhinosinusitis
 Cochrane  review  has  reported  that  there  is  no  robust
urrent  evidence  for  the  use  of  systemic  corticosteroids  as
onotherapy  for  the  treatment  of  acute  rhinosinusitis.82
In  patients  who  received  an  association  of  corticosteroids
nd  systemic  antibiotics,  there  seems  to  be  some  benefit
uch  as  symptomatic  relief,  although  current  data  are  lim-
ted.  The  short-term  benefit  occurs  with  the  reduction  in
ain  scores,  and  there  seems  to  be  improvement  in  the  more
cute  symptoms  of  facial  pain  and  headache. There
s  no  evidence  of  better  long-term  results  (over  2  weeks)
nd  after  10  days  for  the  improvement  observed  in  the
roups  treated  with  the  association  of  corticosteroids  and
224  Mion  OG  et  al.
Table  11  Equivalence,  anti-inflammatory  potency  and  half-life  of  corticosteroids.
Approximate
equivalence  dose  in  mg
Relative  anti-inflammatory
potencya
Biological
half-life  (h)
Hydrocortisone  20  1  8--12
Prednisone 5  3.5--4.0  12--36
Prednisolone 5  4.0  12--36
Methylprednisolone  4  5.0  12--36
Dexamethasone  0.75  30  36--72
Betamethasone  0.6  30  36--72
Deflazacort 7.5  2.5--3.5  24--36
Adapted from hormonal anti-inflammatory drugs: glucocorticoids.80
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ntibiotics  resembles  those  observed  in  the  placebo
roups.83,84 Therefore,  it  appears  corticosteroids  can  bring
ymptomatic  relief  in  the  short  term  as  adjunctive  therapy.
hronic  rhinosinusitis
 recent  systematic  review  suggests  an  important  role  for
ystemic  corticosteroids  in  treating  exacerbations  of  chronic
hinosinusitis  (CRS)  with  polyps,  being  indicated  for  a  short,
ntermittent  treatment  (1--3  weeks).85 This  study  cites  3
revious  systematic  reviews  for  use  in  CRS,86--88 demon-
trating  an  association  with  symptom  improvement,  quality
f  life  questionnaires,  and  polyp  score  when  compared  to
lacebo,  in  a  total  of  5  randomized  controlled  trials.  How-
ver,  the  trials  showed  improvement  only  in  the  short-term,
or  approximately  2--3  weeks,  with  limited  follow-up  of  2--6
onths.
In  CRS  without  polyps,  the  evidence  in  the  literature
s  more  limited,  the  studies  are  heterogeneous  and  lack  a
ontrol  group,  without  randomized  controlled  trials,  demon-
trating  a  lower  level  of  evidence.  The  use  of  systemic
orticosteroids  in  patients  with  CRS  without  polyps  requires
tudies  with  a  more  robust  methodology.
A  meta-analysis  and  a  systematic  review  evaluated  the
ole  of  corticosteroids  in  endoscopic  functional  surgery  of
he  paranasal  sinuses.89 Eighteen  studies  were  included,  for
 total  of  1309  patients.  Studies  with  mixed  populations
f  CRS  with  and  without  polyps  and  the  use  of  systemic
nd/or  topical  corticosteroids  were  evaluated.  The  results
ndicated  a  significant  intraoperative  benefit:  significant
eduction  of  blood  loss,  reduced  surgical  time  and  quality
f  the  surgical  field  improvement.  There  was  no  significant
ifference  regarding  postoperative  pain  and  postoperative
ymptom  scores.  However,  the  postoperative  endoscopic
valuation  scores  were  significantly  better  in  the  corticos-
eroid  group.  The  subgroup  of  patients  with  CRS  with  polyps
ad  a  lower  rate  of  recurrence  when  compared  to  controls.
llergic  rhinitis
he  use  of  corticosteroids  for  a  short  period  of  time  may
e  a  therapeutic  option  in  allergic  rhinitis  patients  who  are
ot  responsive  to  other  treatments.90 The  existence  of  other
ery  effective  treatment  options,  together  with  steroid  use
otential  adverse  effects,  especially  for  a  prolonged  periodf  time,  does  not  justify  their  systematic  and  routine  use
n  allergic  rhinitis.  Therefore,  they  are  not  considered  as  a
rst-line  treatment.91
inal considerations
he  use  of  second-generation  antihistamines  is  recom-
ended  over  the  first-generation  ones  due  to  improved
afety  profile.  Regarding  drowsiness  or  sedation,  the  dose
f  second-generation  drugs  should  be  considered,  as  well  as
ime  of  use  and  individual  sensitivity  of  each  patient.
The  use  of  oral  decongestants  is  useful  in  relieving  symp-
oms  of  acute  nasal  obstruction.  Caution  is  advised  regarding
heir  use  due  to  their  potential  side  effects.
The  use  of  antihistamines  associated  with
ntileukotrienes  becomes  important  in  the  presence
f  monotherapy  failure.
Leukotriene  receptor  antagonists  can  be  used  in  adults
nd  children  with  seasonal  allergic  rhinitis  and  in  preschool
hildren  with  persistent  allergic  rhinitis  due  to  their  efficacy,
igh  safety,  and  tolerability.16 This  line  of  medications  can
till  be  used  as  an  adjuvant  treatment  in  the  treatment  of
hronic  rhinosinusitis.
Oral  corticosteroids  are  useful  as  rescue  medication  for
hronic  rhinosinusitis  with  polyps,  and  are  usually  prescribed
or  a  short  period  of  1--3  weeks.  In  chronic  rhinosinusi-
is  without  polyps,  the  evidence  for  corticosteroid  use  is
ery  limited.  Therefore,  the  analysis  of  a  possible  bene-
t  against  the  potential  risks  of  using  oral  corticosteroids
hould  guide  the  clinical  decision-making.  Similarly,  in  acute
acterial  rhinosinusitis,  the  physician  should  individually
valuate  each  patient,  determine  symptom  severity  and  the
isks  of  oral  corticosteroid  use  and  consider  their  use  as  an
ption  for  symptomatic  relief.
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